FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutics and can be used for stimulating hematopoiesis processes in chemotherapy of tumor diseases. That is ensured by using NF-κB inhibitors as a hemoprotective agent in cytostatic effects.
EFFECT: invention provides effective hemoprotective action in cytostatic effects by stimulating functions of hematopoietic progenitor cells in the post-cytostatic period.
1 cl, 3 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
HEMOPROTECTIVE AGENT | 2018 |
|
RU2696586C1 |
HEMOSTIMULATING AGENT | 2017 |
|
RU2647833C1 |
TISSUE REGENERATION STIMULATING AGENT | 2013 |
|
RU2599289C2 |
METHOD FOR STIMULATION OF GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTION BY BONE MARROW CELLS IN VITRO | 2020 |
|
RU2741784C1 |
METHOD FOR STIMULATION OF ERYTHROPOIETIN PRODUCTION BY BONE MARROW CELLS IN VITRO | 2019 |
|
RU2713122C1 |
METHOD FOR STIMULATING PRODUCTION OF GRANULOCYTE COLONY-STIMULATING FACTOR BY BONE MARROW CELLS IN VITRO | 2021 |
|
RU2770784C1 |
METHOD FOR STIMULATING GRANULOCYTE COLONY STIMULATING FACTOR PRODUCTION BY BONE MARROW CELLS IN VITRO | 2017 |
|
RU2665818C1 |
METHOD FOR STIMULATING PRODUCTION OF ERYTHROPOETIN BY BONE MARROW CELLS IN VITRO | 2016 |
|
RU2628882C1 |
HAEMOSTIMULATING AGENT | 2013 |
|
RU2535021C1 |
HEMOSTIMULATING AGENT | 2013 |
|
RU2514648C1 |
Authors
Dates
2020-06-30—Published
2019-11-19—Filed